Gilead scores a TKO with PhIII filgotinib data, but still faces some big bouts — and doubts — ahead
Gilead’s new Phase III rheumatoid arthritis data on its JAK1 inhibitor filgotinib have sparked a huzzah from the cheering section of Wall Street analysts, but there remain plenty of unanswered questions about the future of this therapy.
Thursday night the big biotech posted positive data from 2 Phase III studies outlining a new batch of positive efficacy and safety scores needed for an approval of this drug — its other and now even more closely watched big late-stage drug in the wake of their selonsertib misfire in NASH. But while the drug beat out placebo handily, Gilead has a much higher mark to hit in a fast-changing field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.